![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AVAX TECHNOLOGIES ANNOUNCES THE COMMENCEMENT OF TWO CLINICAL TRIALS
AVAX TECHNOLOGIES ANNOUNCES THE COMMENCEMENT OF TWO CLINICAL TRIALS
AVAX Technologies has initiated enrollment for its clinical trial of M-Vax for the treatment of patients with Stage III and IV melanoma. The U.S. study is a multicenter trial that will include up to seven clinical sites.
In addition, AVAX has initiated a clinical trial in patients with metastatic peritoneal cancer in France. Both studies will measure safety and include an immunological measure of vaccine activity as measured by Delayed Type Hypersensitivity Testing.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct